Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over the 12‑month period beginning 4 February 2026, including a sub-programme of up to DKK 11,200,000,010.45 running from 6 May 2026 to 1 February 2027.
From 18–22 May 2026, Novo Nordisk repurchased B shares each day in blocks of 210,000 shares, bringing total purchases under the current programme to 2,289,849 B shares with a transaction value of DKK 670,560,306. As of 22 May 2026, the company has repurchased 17,049,028 B shares since 4 February 2026 at an average price of DKK 262.22, for a total of DKK 4,470,560,295.
Following these transactions, Novo Nordisk holds 34,234,329 B shares as treasury shares, equal to 0.8% of its share capital. Total A and B shares outstanding, including treasury shares, are 4,465,000,000.
Novo Nordisk reports that the EU’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation of a once-weekly Wegovy 7.2 mg single-dose pen for people living with obesity. Wegovy 7.2 mg is already available in the EU as three 2.4 mg injections.
The decision is supported by phase 3 STEP UP trials, where injectable semaglutide 7.2 mg produced a 20.7% mean weight loss in adults with obesity and 14.1% mean weight loss in adults with obesity and type 2 diabetes. In STEP UP, 31.2% of patients achieved at least 25% weight loss, and in STEP UP T2D, 21.3% achieved at least 20% weight loss.
The 7.2 mg single-dose pen is already approved in the US and UK, and Novo Nordisk expects to launch it in the EU in Q3 2026, adding a more convenient administration option to its existing obesity portfolio.
Novo Nordisk reports that the EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending EU marketing authorisation for Wegovy® pill, a once-daily 25 mg oral semaglutide, for reducing excess body weight and maintaining long-term weight reduction in adults.
The opinion also supports including SELECT cardiovascular outcomes data in the label, showing Wegovy reduces the risk of major adverse cardiovascular events such as cardiovascular death, heart attack and stroke. In the phase 3b OASIS 4 trial, adherent patients achieved 16.6% mean weight loss, with about one in three reaching at least 20% weight loss.
The safety and tolerability profile matched previous semaglutide weight management trials, and semaglutide is backed by more than 50 million patient-years of real-world safety data. Novo Nordisk notes strong early U.S. demand for Wegovy pill and expects to bring the oral treatment to its first markets outside the U.S. in the second half of 2026, pending approvals.
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. As part of the programme initiated on 6 May 2026, the company bought 1,239,849 B shares for a total of DKK 369,728,627 between 6 and 13 May 2026.
This is within a broader plan to repurchase up to DKK 11,200,000,010.45 of B shares from 6 May 2026 to 1 February 2027, and up to DKK 15 billion over 12 months beginning 4 February 2026. As of 13 May 2026, Novo Nordisk has repurchased 15,999,028 B shares for DKK 4,169,728,617 at an average price of DKK 260.62 per share.
After these transactions, Novo Nordisk holds 33,184,329 B shares of DKK 0.10 as treasury shares, equal to 0.7% of its total share capital of 4,465,000,000 A and B shares.
Novo Nordisk A/S reported transactions in its shares involving persons closely associated with its Chief Financial Officer, in line with EU market abuse rules. Two closely associated individuals, Caroline Munk Esbjerg and Sofie Munk Esbjerg, each received 50 Novo Nordisk B shares as a gift on 2026-05-07 outside a trading venue. The reference prices were DKK 294.30 and DKK 294.25 per share, corresponding to aggregated values of DKK 14,715 and DKK 14,712.50. These notifications are administrative disclosures of gifted shares rather than open‑market trades.
Novo Nordisk A/S has completed a DKK 3,799,999,990 B-share repurchase tranche under its previously announced programme running from 4 February to 4 May 2026. The company bought 14,759,179 B shares at an average price of DKK 257.47 per share.
After these transactions, Novo Nordisk holds 32,148,978 B shares of DKK 0.10 as treasury shares, equal to 0.7% of its 4,465,000,000 total A and B shares. This tranche is part of a wider plan to repurchase up to DKK 15 billion of B shares over a 12‑month period beginning 4 February 2026.
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of shares over 12 months beginning 4 February 2026, the company is running a sub-programme to repurchase B shares for up to DKK 3.8 billion between 4 February 2026 and 4 May 2026.
As of 24 April 2026, Novo Nordisk has repurchased 13,407,992 B shares at an average price of DKK 256.48, for a total value of DKK 3,438,931,195. Following these purchases, Novo Nordisk holds 30,797,791 B shares as treasury shares, equal to 0.7% of its total share capital of 4,465,000,000 A and B shares, including treasury shares.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over a 12‑month period beginning 4 February 2026.
Under the current tranche, Novo Nordisk targets up to DKK 3.8 billion of B share repurchases between 4 February 2026 and 4 May 2026. As of 17 April 2026, it has repurchased 12,257,992 B shares at an average price of DKK 256.87, for a total of DKK 3,148,710,807. Following these transactions, Novo Nordisk holds 28,397,791 B shares as treasury shares, representing 0.6% of its 4,465,000,000 total A and B shares outstanding.
Novo Nordisk reported positive topline phase 3 results from the HIBISCUS trial of once-daily oral etavopivat in adolescents and adults with sickle cell disease. Etavopivat met both co-primary endpoints, showing superior reduction in painful vaso-occlusive crises and superior haemoglobin response versus placebo.
People on etavopivat had a 27% lower annualised rate of crises, and median time to first crisis was 38.4 weeks compared with 20.9 weeks on placebo. At week 24, 48.7% of etavopivat-treated participants achieved a haemoglobin increase greater than 1 g/dL, versus 7.2% on placebo. Etavopivat also reduced the risk of blood transfusion and appeared well tolerated, with a safety profile consistent with earlier studies.
Etavopivat is a once-daily oral pyruvate kinase‑R activator designed as a disease‑modifying therapy for sickle cell disease, which affects around 8 million people globally. The drug has multiple U.S. FDA special designations and Orphan Drug status in both the United States and European Union. Novo Nordisk plans to seek the first regulatory approval for etavopivat in the second half of 2026.